What is the CORONA Remedies PE ratio today?
CORONA Remedies' PE ratio is 68.1 at the 29 October 2026 close (₹2,217.40 a share): a market capitalisation of ₹13,562 crore divided by consolidated net profit of ₹199 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹185 crore) it is 73.3.
What is the CORONA Remedies net worth?
CORONA Remedies' net worth — shareholders' equity in its consolidated balance sheet — was ₹747 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹13,562 crore at the 29 October 2026 close.
What is the CORONA Remedies book value per share?
CORONA Remedies' book value per share was ₹122.12 on 31 March 2026: shareholders' equity of ₹747 crore divided by the 6.12 crore shares in issue. The share price at the 29 October 2026 close was ₹2,217.40.
What is the CORONA Remedies PB ratio (price to book value)?
CORONA Remedies' price-to-book (PB) ratio is 18.16 at the 29 October 2026 close: a market capitalisation of ₹13,562 crore divided by shareholders' equity (book value) of ₹747 crore on 31 March 2026. That is a book value of ₹122.12 per share against a share price of ₹2,217.40.
Is CORONA Remedies debt free?
No. CORONA Remedies had borrowings of ₹143 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.19. Its cash and current investments were ₹44.1 crore, so its net debt was ₹98.7 crore.
What is the CORONA Remedies shareholding pattern?
On 30 September 2026, CORONA Remedies' shares were held by promoters 69.00%, foreign portfolio investors (FII/FPI) 4.21%, domestic institutions (DII) 16.45% (including mutual funds at 16.06%) and retail and other non-institutional investors 10.34%.
What is the CORONA Remedies market cap?
CORONA Remedies' market capitalisation was ₹13,562 crore at the 29 October 2026 close: 6.12 crore shares at ₹2,217.40 each.
What is the CORONA Remedies dividend in 2026 and its record date?
In 2026, CORONA Remedies has declared one dividend: ₹10 with record date 19 June 2026.
What is the CORONA Remedies promoter holding?
Promoters held 69.00% of CORONA Remedies on 30 September 2026, unchanged from the previous quarter, according to the shareholding pattern filed with NSE.
What is the CORONA Remedies debt to equity ratio?
CORONA Remedies' debt-to-equity ratio was 0.19 on 31 March 2026: borrowings of ₹143 crore against total equity of ₹747 crore.
What is the CORONA Remedies free cash flow?
In FY26, CORONA Remedies generated ₹229 crore of cash from operations and spent ₹174 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹55.3 crore.
What are the CORONA Remedies latest quarterly results?
CORONA Remedies' latest results are for Q1 FY27 (April–June 2026), filed on 31 July 2026: consolidated net profit ₹60.1 crore; revenue from operations ₹422 crore.
What is the CORONA Remedies EPS?
CORONA Remedies' basic earnings per share (EPS) were ₹30.27 in FY26.
What is the CORONA Remedies revenue and profit in FY26?
In FY26 (April 2025–March 2026), CORONA Remedies' consolidated net profit was ₹185 crore, on revenue from operations of ₹1,403 crore.
When are the CORONA Remedies next results?
CORONA Remedies will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, the date of the board meeting it has notified to the exchanges.
How does CORONA Remedies compare with its peers?
On FY26 consolidated figures, against Eris Lifesciences, Mankind Pharma and Alembic Pharmaceuticals: CORONA Remedies' operating margin of 18.2% is the third highest of the four (Eris Lifesciences 26.9%, Mankind Pharma 19.1%, Alembic Pharmaceuticals 10.9%; peer average 19.0%).
How does the CORONA Remedies PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, CORONA Remedies' PE ratio is 73.3, the highest of the four: Eris Lifesciences 26.1, Mankind Pharma 53.3 and Alembic Pharmaceuticals 23.2, a peer average of 34.2. Each is the company's market capitalisation at that price divided by its FY26 net profit.
CORONA Remedies vs Eris Lifesciences: how do they compare?
In FY26, CORONA Remedies earned net profit of ₹185 crore on revenue of ₹1,403 crore, against ₹620 crore on ₹3,129 crore for Eris Lifesciences. CORONA Remedies' operating margin was 18.2% (Eris Lifesciences 26.9%). At the 29 October 2026 close, CORONA Remedies' market capitalisation was ₹13,562 crore against ₹16,139 crore for Eris Lifesciences, and its PE ratio on FY26 profit 73.3 against 26.1.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
